Talis Biomedical Net Loss Widens in Q1 While Grant Revenue Increases
05:41 PM EDT, 05/11/2021 (MT Newswires) -- Talis Biomedical (TLIS) reported a Q1 net loss per share of $4.61, wider than a loss of $3.49 per share a year ago.
Analysts polled by Capital IQ had expected a normalized loss of $0.78 per share, if comparable.
Grant revenue rose to $7 million from $399,000 a year earlier. Analysts surveyed by Capital IQ had projected revenue of $5.4 million.
The company is on track to complete a study for COVID-19 assay in a point-of-care environment to support an emergency use authorization application submission to the Food and Drug Administration in Q2.
Price: 10.18, Change: +0.04, Percent Change: +0.39